Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

RenaissanceRe entered the second half of 2026 with strong consolidated underwriting profitability, a 20.1% annualized operating return on average common equity and continued tangible book-value growth. Its underwriting, fee and investment-income model provides meaningful earnings diversification, while substantial share repurchases can enhance per-share compounding. These strengths are balanced by a 103.3% Casualty and Specialty combined ratio, adverse prior-year development in that segment and material contraction in written premiums as management reduces exposure and purchases more retrocession.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026
Low · most bearish analyst$304.00
Mean target$346.40
High · most bullish analyst$438.00
Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$304.0024%

A normalization of catastrophe losses combines with further casualty reserve strengthening, while rate pressure and lower retained premiums reduce underwriting leverage. Investment-market volatility and weaker performance fees then interrupt tangible book-value growth despite capital returns.

Base CaseCentral scenario
$346.4055%
Matches the consensus mean

Consolidated underwriting remains profitable and diversified earnings support book-value compounding, but softer property pricing, declining premium volume and continued casualty reserve caution limit upside.

Bull CaseUpside scenario
$438.0021%

Property underwriting remains highly profitable, catastrophe activity stays contained, investment and fee income remain resilient, and repurchases below intrinsic value accelerate tangible book-value growth. Better casualty pricing and portfolio remediation eventually return the Casualty and Specialty segment below a 100% combined ratio.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Q2 2026 produced a 72.8% consolidated combined ratio, 20.1% annualized operating return on average common equity and 6.2% quarterly growth in tangible book value per common share plus accumulated dividends.
  • The three earnings drivers remained substantial in Q2 2026, including $599.1 million of underwriting income, $83.0 million of fee income and $432.5 million of net investment income.
  • Capital management is shareholder supportive: RenaissanceRe repurchased $350.0 million of common shares during Q2 2026, repurchased another $82.9 million through July 20 and subsequently renewed total repurchase authorization to $750.0 million.
Sign in / Sign up to read more
Key Investment Risks
  • The Casualty and Specialty segment reported a 103.3% combined ratio and $58.0 million of adverse prior-accident-year development in Q2 2026.
  • Q2 gross premiums written declined to $2.994 billion from $3.421 billion, reflecting rate reductions, exposure reductions and portfolio-shaping decisions that may constrain future earned-premium growth.
  • Results remain exposed to catastrophe severity, climate-related risk, reserve-estimation uncertainty, inflation and investment-market volatility.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.